Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine prophylaxis to prevent SARS-CoV-2 infection in immunomediated inflammatory disease patients on biologics/JAK inhibitors
2020-001357-52Phase 4Terminated
- Sponsor
- IDIVAL
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Hydroxychloroquine prophylaxis with Placebo (2 arms). Primary endpoint: Number of patients with positive SARS-CoV-2 serology or PCR. Started May 2020; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001357-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001357-52.